Evidence map›Paper›PMID 28419725›Full record

ArticlePain practice : the official journal of World Institute of Pain2018

Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.

Nicole M Marlow, Kit N Simpson, Ivana A Vaughn, Ara Jo, James S Zoller, Edward B Short

Abstract read
In one paragraph

Article in Pain practice : the official journal of World Institute of Pain, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicole M MarlowDepartment of Health Services Research, Management and Policy, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, U.S.A.
Kit N SimpsonDepartment of Healthcare Leadership and Management, College of Health Professions, Medical University of South Carolina, Charleston, South Carolina, U.S.A.
Ivana A VaughnDepartment of Health Services Research, Management and Policy, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, U.S.A.ORCID 0000-0002-7201-0289
Ara JoDepartment of Health Services Research, Management and Policy, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, U.S.A.
James S ZollerDepartment of Healthcare Leadership and Management, College of Health Professions, Medical University of South Carolina, Charleston, South Carolina, U.S.A.
Edward B ShortDepartment of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, U.S.A.

Funding

Ethnic Differences in Responses to Painful StimuliR37AG033906 · NIA · UNIVERSITY OF FLORIDA · PI FILLINGIM, ROGER B · 2014 to 2023
$12.9M
SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE (SCTR)UL1RR029882 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2009 to 2011
$10.1M
NCRR NIH HHS UL1 RR029882NIA NIH HHS R37 AG033906
6 · The paper itself

Abstract

objectiveTo examine medication adherence and healthcare costs for combination prescription initiators (duloxetine/milnacipran/venlafaxine with pregabalin) vs. monotherapy initiators (duloxetine, milnacipran, venlafaxine, and pregabalin) among patients with fibromyalgia syndrome (FMS).

methodsOur retrospective cohort study used claims data for the South Carolina Blue Cross Blue Shield State Health Plan (SHP). Patients with FMS ≥ 18 years of age, with prescription initiation from July 1, 2007, through June 30, 2010, and SHP enrollment for 12 months pre- and post-index periods were included (combination: n = 100; pregabalin: n = 665; duloxetine: n = 713; milnacipran: n = 131; venlafaxine: n = 272). Medication adherence measures included high adherence (medication possession ratio ≥ 80%) and total supply days. Healthcare costs comprised direct medical expenditures. Propensity score methods of inverse probability of treatment weights were used to control for selection bias due to differing pre-index characteristics.

resultsOdds ratios for high adherence were significantly increased (P < 0.05) among the combination cohort vs. the venlafaxine (2.15), duloxetine (1.39), and pregabalin (2.20) cohorts. Rate ratios for total supply days were significantly higher (P < 0.05) for combination vs. venlafaxine (1.23), duloxetine (1.08), and pregabalin (1.32) cohorts. Expenditures for total health care were significantly higher (P < 0.05) for combination vs. duloxetine ($26,291 vs. $17,190), milnacipran ($33,638 vs. $22,886), and venlafaxine ($26,586 vs. $16,857) cohorts.

conclusionsMedication adherence was considerably better for combination prescription initiators; however, expenditures for total health care were higher. Still, our findings suggest important clinical benefits with the use of combination prescription therapy, and prospective studies of medication adherence are warranted to examine causal relationships with outcomes not captured by healthcare claims databases.

Indexed as

Drug MonitoringAdolescentAdultAgedCohort StudiesDatabases, FactualDrug Therapy, CombinationDuloxetine HydrochlorideFemaleFibromyalgiaHealth Care CostsHumansMaleMiddle AgedMilnacipranPregabalinDuloxetine HydrochlorideMilnacipranPregabalinVenlafaxine Hydrochlorideadherencecomparative effectiveness researchfibromyalgia syndromehealthcare costspharmacotherapy

Identifiers

PMID28419725
PMCPMC5647203

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.